Targeting mitochondrial RNA polymerase in acute myeloid leukemia
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2229 views | HTML 2403 views | ?
Fernando N. Bralha1, Sanduni U. Liyanage2, Rose Hurren2, Xiaoming Wang2, Meong Hi Son1,2, Thomas A. Fung1, Francine B. Chingcuanco1, Aveline Y. W. Tung1, Ana C. Andreazza1,3,4, Pamela Psarianos1, Aaron D. Schimmer2, Leonardo Salmena1,2 and Rebecca R. Laposa1
1 Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
2 Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
3 Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
4 Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Rebecca R. Laposa, email:
Keywords: acute myeloid leukemia, mitochondria, mitochondrial RNA polymerase, electron transport chain, oxidative phosphorylation
Received: August 27, 2015 Accepted: September 25, 2015 Published: October 15, 2015
Acute myeloid leukemia (AML) cells have high oxidative phosphorylation and mitochondrial mass and low respiratory chain spare reserve capacity. We reasoned that targeting the mitochondrial RNA polymerase (POLRMT), which indirectly controls oxidative phosphorylation, represents a therapeutic strategy for AML. POLRMT-knockdown OCI-AML2 cells exhibited decreased mitochondrial gene expression, decreased levels of assembled complex I, decreased levels of mitochondrially-encoded Cox-II and decreased oxidative phosphorylation. POLRMT-knockdown cells exhibited an increase in complex II of the electron transport chain, a complex comprised entirely of subunits encoded by nuclear genes, and POLRMT-knockdown cells were resistant to a complex II inhibitor theonyltrifluoroacetone. POLRMT-knockdown cells showed a prominent increase in cell death. Treatment of OCI-AML2 cells with 10-50 µM 2-C-methyladenosine (2-CM), a chain terminator of mitochondrial transcription, reduced mitochondrial gene expression and oxidative phosphorylation, and increased cell death in a concentration-dependent manner. Treatment of normal human hematopoietic cells with 2-CM at concentrations of up to 100 µMdid not alter clonogenic growth, suggesting a therapeutic window. In an OCI-AML2 xenograft model, treatment with 2-CM (70 mg/kg, i.p., daily) decreased the volume and mass of tumours to half that of vehicle controls. 2-CM did not cause toxicity to major organs. Overall, our results in a preclinical model contribute to the functional validation of the utility of targeting the mitochondrial RNA polymerase as a therapeutic strategy for AML.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.